Nova Minerals is no longer just another Alaska gold junior waiting on a study. The company spent the past year converting a Department of War award into steel, a Nevada parent, and a summer field season that management describes as the shift from exploration into execution. The debate is whether that award bought a real path to domestic antimony output or merely financed a plan whose ore body, permits, and year-round road still sit in front of first product.
The award to Alaska Range Resources is the mechanism that changed the capital stack. Title III money is meant to extract, concentrate, and refine stibnite into military-grade antimony trisulfide, which is why a forty-three million grant can fund stage-one plant and fleet while the gold program still lives on equity. That split is the bull case in one sentence: the government pays for the antimony build, and shareholders keep the multi-million-ounce gold option. The bear case is the reverse. Stage one does not define a mineral resource for antimony, does not finish the West Susitna road, and does not replace the older gold scoping study that used a far lower metal price than the market now clears.
Cash at the March quarter still covered field work and plant mobilization, and the remaining award is restricted to the antimony workstream. The equity, after a December raise and a June redomicile onto the NYSE American, now prices a mid-two-hundred-million claim on both stories at once. The next year resolves whether Port MacKenzie becomes a working plant and whether an updated gold resource and pre-feasibility study can stand on their own if antimony slips.